{"name":"Santen Pharmaceutical Asia Pte. Ltd.","slug":"santen-pharmaceutical-asia-pte-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eybelis ophthalmic solution 0.002%","genericName":"Eybelis ophthalmic solution 0.002%","slug":"eybelis-ophthalmic-solution-0-002","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Eybelis ophthalmic solution 0.002%","genericName":"Eybelis ophthalmic solution 0.002%","slug":"eybelis-ophthalmic-solution-0-002","phase":"marketed","mechanism":"Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZjdGdjg2VUI5UVRfb0xfa3hmamhYVnlYV0o0UUUwQlk5OUZCbGV6SlhFZWgzeWhReEdNWVI2X0lkQ2Z5eWdlNjlSMkZHLVJHVVN2VEktWTJZLVNCeEo0c0Fadnl3d0tVVGFHV3ZIaWE0cy14V2ZDSkVaSHhtN1E3cnZFM1RRWFhEY2UyU0RfWGdKelBi?oc=5","date":"2026-01-08","type":"regulatory","source":"Yahoo Finance","summary":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% - Yahoo Finance","headline":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic S","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPMm5DZGZGd0ZyQm9YWlR3djlMYzdEaFh6bWtJZXd2YzN1ZEk0bXhJV2l3S0k3eVVqS0hBN1FMcGMxSXpiVXpIT3NOcEJQLXJRRm81YllNUFptUVVUdm1iVlpCQXFfQ3dMb2s3TUwxc0tCS2FqUjhBcGdHME1FRzlvQXM3UWVheklOZnRreHY2MUhobXBNTVdmakVCZ183WWdvb0wyc2hZY3dFWGdEWFE?oc=5","date":"2025-12-08","type":"pipeline","source":"Healthcare Asia Magazine","summary":"Santen–SERI $16.2m project targets glaucoma, myopia treatment - Healthcare Asia Magazine","headline":"Santen–SERI $16.2m project targets glaucoma, myopia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBuVlV3RzZlM2F2bnpxQjdITlNNX0I3ZGdBWE1qc25wLVhTdGdEd2dFT0djcWV2SUwwaGxwREtuMGVuU0Vtck45bW1RaWhhSkFtRlZxWktqOWl6TFl3OUg3cV9MMG5tY25aOW8yVGFn0gFyQVVfeXFMTVdxSVNxOThMVTdnR2tkYk9rUUxDVkFjeDFzUEpDYnE4TVJxQlo4eE1hQ0U3eEpNM1dCeDhXYzBFMEVPU2NjRlpScHRVODczakJGaTVJQUJCZFFxbFczc2pKa0tKbGp2SmxZVnR3Y2RWSHVR?oc=5","date":"2025-11-05","type":"pipeline","source":"koreabiomed.com","summary":"Santen Korea enters retinal disease market with exclusive rights to Novartis’ Beovu and Lucentis - koreabiomed.com","headline":"Santen Korea enters retinal disease market with exclusive rights to Novartis’ Beovu and Lucentis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQLVJsRjJIeDZOUDNtejNOXzQwRWJ2cnhqY2lneU5aYy1lVFFiWTl6SjJTYkZLOGVhY3piZkpJUXVHa3oyNGdkVVlTdzBwUjFWdGFrdXBpVF9HZFpVUlJ3LWFDQVQ1RkJob3JMdUkwR3c0MDRJeENhTmlVTDdOSmRiY0dnSEtJdDM1dS1Lb0FBRW0zcWRhTlZfWjdYazlzZw?oc=5","date":"2025-08-19","type":"deal","source":"Fierce Biotech","summary":"China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal - Fierce Biotech","headline":"China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNd1gxZ0tUU0dxMkN2bjRNQVptQXBJODBXTEpsRklRMFc5TkVCN0lOUGM3SUh3eEFTakUwZGRJbW1vM2V2aEFoMGFXZFc1b181MWJoY054ckx3WGR6RzhnakhPTkVxeUF1bkZfXzd3YW53NFI5T0xyS2xlcFBvT1FJNXN4UVY4NXVLU1dnRHdGVFNocnVYaW92RkQtVmZjZWxra20yLXl3MFFFZnpWbG5LeDI0TWxNSWQyUjZUTUxqN0FOSER2bF9tQl81b19McE5nSGQ4VzRvc0pNbmttekxGVThZVjhSaEEwMHkyeHliRVZhU19IYXF1clFRdFZja2VfS0FwbHNqUWoycUU4YXBsZjVONmxhRlhhVVE?oc=5","date":"2025-08-18","type":"pipeline","source":"PR Newswire","summary":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PR Newswire","headline":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQa2FuMmlNTjdpcFZCZ24xSUVmRWpFSTFlc0FSSXNQMkUzMWlYdW1aTVgya0NkemhMck5ZbUtPNUFSTGQyM0VuVEtwUVVXaTMxUC1qRlBqR05yMWZud3d0T3lKVHlnd1o2SXVaYWdCX1l2TXJjV3Bidk9CRUYwX3VrQU9wVGlBR1hvSUM4dkVUM2pGSjQ4?oc=5","date":"2025-03-21","type":"pipeline","source":"The Pharma Letter","summary":"Santen to launch Ryjusea Mini ophthalmic solution in Japan - The Pharma Letter","headline":"Santen to launch Ryjusea Mini ophthalmic solution in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFNmREhVQ3FONm96VHlYQkJRcnJ4QWp2UlBwVTdmLVB2SFJ5WE1xUEp6N1RmZDkyZUFvckdPLUJXNVZ3LXc4N29NZ3RLNU5PUVNvMFJ4YzdUcmY1MzJSS1dLTTF3ZDVNS0UyZUhNNzJxSHRQNFQ3X0ZBN1F4RzBtdWlsWXJUdmRmZW00Zmw3TzAyaE80cUV4aTdLYTJ4UmRnaGtHMjZhVkZiZw?oc=5","date":"2023-07-25","type":"pipeline","source":"BioWorld News","summary":"Santen sells North American ophthalmic portfolio to Visiox, Harrow - BioWorld News","headline":"Santen sells North American ophthalmic portfolio to Visiox, Harrow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1BNW51ZWpfUFdBdGlNZ0VCY0dLc05vY0MxN292ejJkMGExNTYyc1hyaWhvVzZDX3RmdFR3VnFPaHUzOHhEYVB6VHhnblVGMEtsR2VrdFBhbGZEMUF1QWlkanoxYUZLNWxLcUhzOVN0ZkZha0It?oc=5","date":"2023-01-18","type":"pipeline","source":"PwC","summary":"A conversation with Santen’s CIO: What does an IT organisation need to survive and win in the global market? (Part 1) - PwC","headline":"A conversation with Santen’s CIO: What does an IT organisation need to survive and win in the global market? (Part 1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNODlnNk1xSl9kWFF5dnVmYnFxTm1EVUcyaFJ0ZXR5clpvSURocTRLZzdBeHY3RWZ0b2hIcTlrRXBBdE5lc2FLWUxFWkxKTXVFMmRkVlVTbzN0aS1tWXMwUFlJOC1SVm1LRVhnSkZKMTlKMWFlUVktMnhieF9UN0dsbXhIXzJSemlPUWhsWC1sMkN4UWtqZkZka0k2bV9iRFFLSElfU1Jma1RVSlpqdE9keXdpYll5aVNONm9BWFlORldNWWpSX01ZUnBlSHdUNzRSRTd5RUsxVzRXUEZEOFNTb004Z0JCdzlSM0pxU2x3ZVIwam5BRmM2elhGWE5JeUhtSzJxdzFKOA?oc=5","date":"2021-12-07","type":"deal","source":"Business Wire","summary":"Aerie Concludes Exclusive License Agreement With Santen for Rhopressa - Business Wire","headline":"Aerie Concludes Exclusive License Agreement With Santen for Rhopressa","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2020-07-28","type":"pipeline","source":"GlobeNewswire","summary":"Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, - GlobeNewswire","headline":"Santen and RVL Pharmaceuticals, Inc., an Osmotica Company,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPT3lwMXNVaUNMY3lyV0RfVFFhWlI1aUNGRWZQeVVtUTM2UUFkU1JJUkxGRW1JNlFUX1B3NmZ3YlFFY21mSHNhSG5ROFRDc0FCcngzc0wxaWVKbEQtWHpWRE9iMFF1SGJqYXI2SU5LYkpkR2d0bmRyZTh6RmJaaDA3S2FTem1lOEsxUGFjM1V6X3hwYTFzVmx3X3IyV0pWR0lhUkdUamhhcUpjYkNBaFJKM1JCU1dIdkJXV1puU0ZqRmQ5RVhW?oc=5","date":"2020-05-21","type":"pipeline","source":"News-Medical","summary":"Santen appoints Dr Sophia Pathai as new Vice President of Medical Affairs EMEA - News-Medical","headline":"Santen appoints Dr Sophia Pathai as new Vice President of Medical Affairs EMEA - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNX1B1NThJYjhoT01HR2xNcjYxanhYQ3d0WW1uYnNxS1h3NEZZZmVTWlptS3pLaXdieHk2WGh5WFFfQlBuQXJ4ZTk4d0drQXdPa0dpZW1CR1J0U01EdmVOcHBMME1lT1B0b1FRNzVjb0F0S3pxWGFJaUhqdjJldzd0WXlrSm9LazRDY2ZXbk44eXpWUjhyQmJCR1hEQWRZVWNqN1hFbzlUd0FaLUxPZWxmZzc4Y0lna0xwaFltLW5jcFRORHhEVEdzS0Rpa0dmY2F6YjdSNnhPRzBkT1k4d0sxbzRqSExrNENPQldfN1B3dC1BUQ?oc=5","date":"2019-02-26","type":"pipeline","source":"Aptar","summary":"Aptar Pharma Ophthalmic Squeeze Dispenser launched with Santen's Taflutan / Saflutan in the EU - Aptar","headline":"Aptar Pharma Ophthalmic Squeeze Dispenser launched with Santen's Taflutan / Saflutan in the EU","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}